The European epigenetics market is expected to register a CAGR of nearly 14.5% over the forecast period. Factors that are responsible for the growth of this market include the increasing incidence and prevalence of cancer, the increasing funding for R&D in healthcare, and rising epigenetic applications in non-oncology diseases.
The epigenetics market is increasing in the European region. For instance, according to WHO, more than 3.7 million new cases of cancer and 1.9 million deaths occur due to cancer every year, and cancer represents the second most important cause of death and morbidity in the European region. Epigenetics is used in the study of changes in gene expression, which are useful in cancer diagnosis. This depicts the large pool of cancer patients, which will propel the growth of the epigenetics market. So, with the increasing cancer prevalence, the market is expected to grow. However, factors, such as the rising cost of instruments are expected to restrain the growth of the market.
Key Market Trends
Oncology is Expected to Grow Faster in the Application Segment
In the last few years, the market has been a golden age for cancer genetics. The cost of gene sequencing has dropped low enough for researchers to read the genomes of many thousands of patients, comparing the DNA of the diseased and healthy tissues to find the mutations associated with tumor formation and growth, which is associated with cancer. The epigenetic innovations are unobtrusively crafting a toolbox for the powerful drugs to treat cancer. And the rising prevalence of cancer in the European region is expected to drive the oncology application in the European epigenetic market.
Competitive Landscape
The European epigenetic market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. . Some of the major players of the market are Merck & Co., Qiagen, Roche, Thermo Fisher Scientific, and Illumina Inc., among others.
Reasons to Purchase this report:
This product will be delivered within 2 business days.
The epigenetics market is increasing in the European region. For instance, according to WHO, more than 3.7 million new cases of cancer and 1.9 million deaths occur due to cancer every year, and cancer represents the second most important cause of death and morbidity in the European region. Epigenetics is used in the study of changes in gene expression, which are useful in cancer diagnosis. This depicts the large pool of cancer patients, which will propel the growth of the epigenetics market. So, with the increasing cancer prevalence, the market is expected to grow. However, factors, such as the rising cost of instruments are expected to restrain the growth of the market.
Key Market Trends
Oncology is Expected to Grow Faster in the Application Segment
In the last few years, the market has been a golden age for cancer genetics. The cost of gene sequencing has dropped low enough for researchers to read the genomes of many thousands of patients, comparing the DNA of the diseased and healthy tissues to find the mutations associated with tumor formation and growth, which is associated with cancer. The epigenetic innovations are unobtrusively crafting a toolbox for the powerful drugs to treat cancer. And the rising prevalence of cancer in the European region is expected to drive the oncology application in the European epigenetic market.
Competitive Landscape
The European epigenetic market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. . Some of the major players of the market are Merck & Co., Qiagen, Roche, Thermo Fisher Scientific, and Illumina Inc., among others.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Diagenode Inc.
- Epitherapeutics
- Illumina, Inc.
- Merck & Co.
- Qiagen
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific
- Zymo Research Corporation
Methodology
LOADING...
